NEXGEL Eyes $35M Pro Forma Revenue After Acquiring Celularity's Wound Segment

NEXGEL is projecting a significant leap in its financial scale, anticipating pro forma annual revenue of approximately $35 million following its strategic acquisition of the wound care segment from Celularity Inc. This move instantly reshapes the hydrogel technology company's market position, transforming its revenue profile through the integration of an established product line and customer base in the advanced wound management sector.

The acquisition centers on Celularity's wound segment, which includes its portfolio of placental-derived biomaterial products designed for chronic and surgical wound healing. By folding these assets into its operations, NEXGEL gains immediate commercial traction and a more diversified revenue stream beyond its core hydrogel offerings. The projected $35 million pro forma figure represents a combined operational view, signaling how the company expects the merged entities to perform on an annualized basis post-transaction.

This calculated expansion places NEXGEL in a stronger competitive stance within the specialized wound care market, a sector driven by innovation and addressing complex clinical needs. The revenue target underscores the transaction's immediate financial rationale, aiming to create a larger, more resilient commercial platform. Success now hinges on effective integration, cross-selling opportunities, and leveraging combined R&D to solidify its footprint against established medical technology players.